Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03568669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Sponsor changed: Debra Weese-Mayer to Ilya Khaytinv10
  2. Notable Enrollment target: 500 to 1000v9
  3. Minor Re-verified, no change to tracked fieldsv8
  4. Notable Enrollment target: 300 to 500v7
  5. Notable Enrollment target: 200 to 300
    • Study sites: 3 to 4
    • Collaborators: 3 to 4
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Re-verified, no change to tracked fieldsv5
  2. Minor Site contacts updated at 1 of 3 sitesv4
  3. Minor 2 versions Re-verified since Jul 5, 2018, no change to tracked fieldsv2-v3
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that frequently alters oxygen delivery to the brain. In CCHS, neurocognitive function has been of great concern because of the potential for repeated hypoxemia and hypercarbia in activities of daily living in addition to hypoventilation with related hypoxemia and hypercarbia during sleep. As the world's leading referral center for CCHS, the Center for Autonomic Medicine in Pediatrics (CAMP) is engaged in ongoing research to identify factors that impact neurocognitive performance in patients with CCHS in order to optimize clinical management and improve long term neurocognitive outcomes. The purpose of this IRB-approved research study is to implement the NIH Toolbox as a standard measurement of cognitive health in patients with CCHS. Further, the study aims to determine how intrinsic and extrinsic disease factors such as age at diagnosis, PHOX2B mutation type and genotype, and nature of past and present artificial respiratory intervention affect the NIH Toolbox Cognitive scores of individuals with CCHS. Eligible participants will complete a 45-minute NIH Toolbox assessment and parents (or adult participants) will complete an associated, 15-minute Research Electronic Data Capture (REDCap) questionnaire.
Trial Details
NCT Number NCT03568669
Lead Sponsor Ilya Khaytin
Collaborators: Ann & Robert H Lurie Children's Hospital of Chicago, Seattle Children's Hospital, Children's Hospital Los Angeles, Children's Hospital of Philadelphia
Conditions
(from sponsor)
Congenital Central Hypoventilation Syndrome, Congenital Central Hypoventilation, CCHS, CCHS With Hirschsprung Disease, CCHS With Neural Crest Tumor, CCHS With Neuroblastoma
Related terms Congenital central hypoventilation syndrome, Sleep Apnea, Central
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov